Inactive Instrument

THOE HEAL Stock

THRN

US8852601090

Analysts' recommendations: THOE HEAL

23-10-11	Evercore ISI Downgrades Thorne HealthTech to In Line From Outperform, Raises Price Target to $10.20 From $8	MT
23-08-30	TD Cowen Downgrades Thorne HealthTech to Market Perform From Outperform, Adjusts Price Target to $10.20 From $8	MT
23-08-11	Canaccord Genuity Adjusts Price Target on Thorne HealthTech to $7 From $6, Maintains Buy Rating	MT
23-04-04	Canaccord Genuity Adjusts Price Target on Thorne HealthTech to $6 From $5.50, Keeps Buy Rating	MT
22-11-17	Canaccord Genuity Starts Thorne HealthTech at Buy With $5.50 Price Target	MT

More recommendations

Managers and Directors: THOE HEAL

Manager	Title	Age	Since
Colin Watts CEO	Chief Executive Officer	60	-
Saloni Varma DFI	Director of Finance/CFO	47	2023-03-31
Jacqueline Jacques CTO	Chief Tech/Sci/R&D Officer	-	2021-12-31

Director	Title	Age	Since
Thomas McKenna BRD	Director/Board Member	66	2009-12-31
Rajan Shah BRD	Director/Board Member	-	-

More insiders

Thorne HealthTech, Inc. is a science-driven wellness company that is developing solutions for a personalized approach to health and wellness. The Company's vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products and services that individuals to take a proactive approach to improve and maintain their health over their lifetime. By combining its multi-omics database, artificial intelligence (AI) and digital health content with its science-backed nutritional supplements, it delivers a total system for wellness. Thorne provides health tests, education, and products that support the optimization of health. Onegevity provides a comprehensive molecular portrait and personalized recommendations for an individual's health, based on integrated analysis of longitudinal blood, genetics and gut microbiome profiles. It offers health tests to generate comprehensive, personalized molecular portraits for its customers.

Employees

544

Sector

More about the company

08-03	The Procter & Gamble Company (NYSE:PG) entered into a definitive agreement to acquire Thorne Research, Inc. from L Catterton X LP, a fund managed by L Catterton Management Limited for $3.8 billion.	CI
04-13	[Solidcore] Unveils 2026 Core Collective Expanding Member Experience Through Wellness Partnerships	CI
03-12	Thorne Becomes Exclusive Vitamins, Minerals and Supplements Partner of Miami Open	CI
03-09	Thorne Announces Results of Consumer Studies Validating Benefits of Magnesium Glycinate and Ginseng Plus	CI
12-15	Unrivaled Names Thorne as Official Sports Nutrition Partner	CI
25-09-08	Thorne Unveils its Creatine Campaign Spotlighting the Supplement's Wide-Ranging Benefits Including Performance, Endurance and Cognition	CI
25-05-19	Thorne Forms Scientific Advisory Board	CI
25-02-11	UFC and Thorne Announces Global Partnership Renewal	CI
24-08-08	Thorne Appoints Mary Beech as Chief Growth Officer	CI
23-12-20	Thorne Healthtech Announces Innovation Arm Under Thorne Ventures	CI
23-10-16	Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index	CI
23-10-15	L Catterton Partners completed the acquisition of Thorne HealthTech, Inc. from Mitsui & Co., Ltd., Kirin Holdings Company, Limited, Helsinn Therapeutics (U.S.), Inc., Diversified Natural Products, Inc. and others.	CI
23-10-13	Thorne HealthTech, L Catterton Announce Expiration of Oustanding Shares Tender Offer	MT

24-07-22	THOE HEAL : Thorne Debuts Find Your Way Campaign With International Entrepreneur Investor And Model Karlie Kloss	PU
24-05-02	THOE HEAL : Thornes Fear Of Aging Report	PU
24-04-01	THOE HEAL : Drawbridge Secures Fda Clearance For At Home Blood Sampling Device Nanodrop	PU
23-10-16	L Catterton Completes Acquisition of Thorne HealthTech, Inc.	PR
23-10-13	L Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender Offer	PR

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/16/23	MITSUI & CO., LTD.	Tender	Company	15,730,750	29.1112%
10/16/23	William McCamy	Issuer sale	Chairperson	1,928,364	3.5686%
10/16/23	Thomas McKenna	Issuer sale	Chief Operating Officer	2,266,037	4.1935%

THOE HEAL Stock

Stocks

THRN

US8852601090

Latest news : THOE HEAL

Analysts' recommendations: THOE HEAL

Press Releases: THOE HEAL

Quotes and Performance

Managers and Directors: THOE HEAL

Latest insider transactions

Company Profile